Significant Underuse of Warfarin in Patients with Nonvalvular Atrial Fibrillation: Results from the China National Stroke Registry

详细信息    查看全文

• 作者：Chunjuan Wang ; MD^&lowast ; ; Zhonghua Yang ; MD^&lowast ; ; Chunxue Wang ; MD^&lowast ; ; Yilong Wang ; MD^&lowast ; ; Xingquan Zhao ; MD^&lowast ; ; Liping Liu ; MD^&lowast ; ; David Z. Wang ; DO^&dagger ; ; Hao Li ; PhD^&lowast ; ; Yongjun Wang ; MD^&lowast ; ; ^{yongjunwang1962@gmail.com" class="auth_mail}
• 关键词：Anticoagulation ; atrial fibrillation ; warfarin ; stroke management ; transient ischemic attack
• 刊名：Journal of Stroke and Cerebrovascular Diseases
• 出版年：May-June 2014
• 年：2014
• 卷：23
• 期：5
• 页码：1157-1163
• 全文大小：611 K

文摘

Warfarin reduces the risk of stroke in patients with atrial fibrillation (AF) but is often underused in clinical practice. We aimed to examine the current state of warfarin use in nonvalvular atrial fibrillation (NVAF) patients with first-ever ischemic stroke (IS) or transient ischemic attack (TIA) in China and to analysis factors causing such underuse.

Methods

By accessing the China National Stroke Registry, data on consecutive patients with known NVAF who developed first-ever IS or TIA were studied. Proportion of warfarin use was estimated in those patients with known NVAF who should be eligible for anticoagulation therapy. Factors associated with warfarin underuse were identified by multivariate logistic regression.

Results

Of 11,080 patients with first-ever IS or TIA, 996 (9.7%) had NVAF and no contraindications to anticoagulation therapy and 592 of them had history of AF. Among these patients, only 96 (16.2%) were on warfarin and 496 (83.8%) were not. In those patients on warfarin, only 1 of his international normalized ratios on admission was in the therapeutic range of 2.0-3.0. Based on the CHADS₂ scores, about 20.2% low-risk AF patients took warfarin; however, only 15.2% moderate and 16.4% high-risk patients were on warfarin. Older patients and patients with history of coronary heart disease (CHD) were less likely to be given warfarin, whereas patients with history of prestroke antiplatelet use were more likely to take warfarin.

Conclusions

We found that warfarin was significantly underused in patients with known NVAF in China. Age and CHD and prestroke antiplatelet therapy were related factors.